Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cost effectiveness of long-acting risperidone: what can pharmacoeconomic models teach us?

Literature DB >> 16416757

Cost effectiveness of long-acting risperidone: what can pharmacoeconomic models teach us?

Lieven Annemans¹.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2005 PMID： 16416757 DOI： 10.2165/00019053-200523001-00001

Source DB: PubMed Journal: Pharmacoeconomics ISSN： 1170-7690 Impact factor: 4.981

× No keyword cloud information.

15 in total

1. Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada.

Authors: P S Chue; Bart Heeg; Erik Buskens; Ben A van Hout
Journal: Pharmacoeconomics Date: 2005 Impact factor: 4.981

2. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.

Authors: Natalie C Edwards; Julie C Locklear; Marcia F T Rupnow; Ronald J Diamond
Journal: Pharmacoeconomics Date: 2005 Impact factor: 4.981

3. Modelling the treated course of schizophrenia: development of a discrete event simulation model.

Authors: Bart Heeg; Erik Buskens; Martin Knapp; Gerda van Aalst; Pieter J T Dries; Lieuwe de Haan; Ben A van Hout
Journal: Pharmacoeconomics Date: 2005 Impact factor: 4.981

4. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.

Authors: Gerd Laux; Bart Heeg; Ben A van Hout; Angelika Mehnert
Journal: Pharmacoeconomics Date: 2005 Impact factor: 4.981

1. Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America.

Authors: Rogelio Apiquian; Rodrigo Córdoba; Mario Louzã
Journal: Neuropsychiatr Dis Treat Date: 2010-12-22 Impact factor: 2.570

2. Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic.

Authors: Pierre Chue
Journal: Neuropsychiatr Dis Treat Date: 2007-02 Impact factor: 2.570

2 in total

Cost effectiveness of long-acting risperidone: what can pharmacoeconomic models teach us?

1. Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada.

2. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.

3. Modelling the treated course of schizophrenia: development of a discrete event simulation model.

4. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.

5. Modelling in economic evaluation: an unavoidable fact of life.

Review 6. Measuring the costs of schizophrenia. Implications for the post-institutional era in the US.

7. Relapse in schizophrenia: costs, clinical outcomes and quality of life.

Review 8. Cost-of-illness studies in diabetes mellitus.

Review 9. Long-term depot antipsychotics. A risk-benefit assessment.

Review 10. An economic evaluation of schizophrenia--1991.

1. Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America.

2. Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic.